Allakos shares are trading lower. The company announced results from the single and multiple ascending Phase 1 study of intravenous AK006 in healthy volunteers.
Portfolio Pulse from Benzinga Newsdesk
Allakos shares are trading lower following the announcement of results from the Phase 1 study of intravenous AK006 in healthy volunteers.
June 25, 2024 | 8:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Allakos shares are trading lower after the company announced results from the Phase 1 study of intravenous AK006 in healthy volunteers.
The announcement of the Phase 1 study results has led to a negative market reaction, causing Allakos shares to trade lower. This suggests that the results may not have met investor expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100